The Farm Bill, the FDA, and What Comes Next for CBD Patients

The Farm Bill, the FDA, and What Comes Next for CBD Patients

By Cope Now Clinical Content Team  |  Published March 2026  |  Last Updated May 2026

Regulatory note: This article reflects the regulatory landscape as of March 2026. Hemp-derived CBD regulation is an actively evolving area. Readers should seek current information from official government sources for the most up-to-date regulatory status.

If you have been using retail CBD products and have heard that regulations are changing, your concern is well-founded. The regulatory landscape for hemp-derived cannabinoid products has been shifting significantly. What that means for patients who use retail CBD is not simple, and the answers depend on regulatory developments that continue to evolve.

This article explains the regulatory history that created the retail CBD market, what has been changing in the regulatory environment, what patients who use retail CBD should understand about those changes, and what a structured, clinically supervised alternative looks like for patients who want a compliant pathway.

This is not a legal document and does not constitute legal advice. Regulatory frameworks in this area are actively evolving. The goal here is to explain the landscape clearly so patients can make informed decisions about their own healthcare.

Educational Disclaimer:  This article is for informational purposes only. It is not medical or legal advice. Regulatory information reflects the landscape as of publication and may change. Not all patients are eligible for clinical evaluation. No guarantee of prescription or outcome. Compounded formulations are not FDA-approved.

Table of Contents

1.  How the retail CBD market was created

2.  What the Farm Bill actually did and did not do

3.  What has been changing in the regulatory environment

4.  What this means for patients using retail CBD

5.  What the FDA's position has been

6.  The compounding pharmacy pathway and regulatory compliance

7.  What patients can do now

8.  Frequently asked questions

1. How the Retail CBD Market Was Created

The retail CBD market as most patients know it was created largely by the 2018 Farm Bill. That legislation removed hemp, defined as cannabis containing 0.3 percent delta-9 THC or less by dry weight, from the federal Controlled Substances Act. This change made hemp-derived CBD products legal for interstate commerce at the federal level.

The practical result was a rapid expansion of retail CBD products across online marketplaces, health food stores, pharmacies, and specialty retailers. Products were marketed as dietary supplements. No FDA pre-market approval was required. Quality standards were inconsistent. Labeling accuracy varied. Clinical oversight was absent.

The 2018 Farm Bill created access at scale but did not create clinical infrastructure. Patients gained easy access to CBD products. They did not gain access to clinical evaluation, individualized dosing, medication review, or ongoing oversight. The market built around product margins. The clinical pathway that patients were actually looking for was never built as part of the retail expansion.

2. What the Farm Bill Actually Did and Did Not Do

Understanding the current regulatory moment requires clarity about what the 2018 Farm Bill actually established and what it left unresolved.

What it did:

• Removed hemp from the federal Controlled Substances Act
• Allowed interstate commerce of hemp-derived products
• Directed the USDA to establish hemp production regulations
• Created the legal foundation for the retail CBD market

What it did not do:

• Establish FDA approval or oversight of CBD as a dietary supplement or food additive
• Create clinical standards for CBD products
• Require dosing accuracy, ingredient testing, or quality consistency for retail products
• Build a clinical pathway for cannabinoid therapy
• Address the gap between retail CBD and clinical cannabinoid care

The Farm Bill resolved the federal legality question for hemp. It did not resolve the clinical oversight question for cannabinoid patients. That gap between legal access and clinical care is the structural problem that Prescription Cannabinoid Care was built to address, independent of whatever regulatory changes follow.

3. What Has Been Changing in the Regulatory Environment

The regulatory environment for retail hemp-derived CBD products has been undergoing active review and change since the 2018 Farm Bill created the market. Several developments have contributed to the current landscape.

Congressional attention

Congress has revisited the hemp provisions of the Farm Bill through the reauthorization process. Legislative proposals have included provisions that would tighten oversight of hemp-derived products, impose THC concentration limits on certain product types, and create new regulatory pathways for cannabinoid products that fall outside the current supplement framework.

FDA positioning

The FDA has consistently stated that CBD is not legally marketable as a dietary supplement or food additive under existing regulations, based on its prior approval of a CBD-based prescription drug. The FDA has issued warning letters to CBD companies making unlawful claims and has repeatedly called for Congress to establish a clear regulatory framework for CBD products.

State-level variation

Individual states have taken varying approaches to hemp-derived CBD regulation, with some states imposing stricter requirements than federal baseline and others taking more permissive approaches. The result is a patchwork regulatory environment that affects product availability and consistency depending on where a patient is located.

Market consolidation and quality concerns

Independent testing of retail CBD products has repeatedly found significant variability between labeled and actual CBD content in many products. Some products have been found to contain higher-than-labeled THC levels. The absence of mandatory pre-market testing has meant that product quality remains inconsistent across the retail market.

Note: Regulatory timeline reflects publicly available information as of March 2026. Specific implementation details may change. Consult official government sources for current status.

4. What This Means for Patients Using Retail CBD

For patients who have been using retail CBD products, the regulatory changes create a landscape that is worth understanding clearly.

Product availability may be affected

Some retail hemp-derived products that were previously available may become more restricted or unavailable as regulatory changes take effect. This depends on the specific product type, THC concentration, and how the product is categorized under applicable regulations.

Product consistency remains a concern

Regardless of regulatory changes, the structural issues with retail CBD quality and consistency have not been resolved for most of the market. Labeling accuracy, actual CBD content, and THC levels continue to vary across products.

The clinical gap remains unchanged

Regulatory changes to the retail market do not automatically create a clinical pathway. The absence of clinical evaluation, individualized dosing, and medical oversight that has characterized the retail CBD experience is a structural feature of the retail model, not a regulatory one. Regulatory change does not add clinical infrastructure.

A compliant clinical pathway exists

Patients who want to continue exploring cannabinoid therapy within a regulated, clinically supervised framework have a specific pathway available to them. Prescription Cannabinoid Care operates within the regulated compounding pharmacy framework and is governed by a separate regulatory structure from whatever changes affect the retail supplement market.  For many patients, the uncertainty is not just about product availability. It is about whether the way they have been accessing cannabinoid products was ever designed to provide clinical clarity in the first place.

5. What the FDA's Position Has Been

The FDA's position on CBD in food and dietary supplements has been consistent since 2018. The agency has stated that CBD is not legally marketable as a dietary supplement or food additive under the Federal Food, Drug, and Cosmetic Act because CBD was the subject of prior clinical investigations and approved as a drug before any supplement notification was submitted.

This position has created a regulatory ambiguity that has shaped how the retail CBD market has developed since 2018. The FDA has not taken broad enforcement action against the retail CBD market but has issued warning letters to specific companies making unlawful health claims.

The FDA has repeatedly called for Congress to establish a new regulatory framework specifically for CBD products that would address the gap between the current supplement regulations and the actual market reality. That framework has not yet been fully established as of the date of this article.

What the FDA has approved is one CBD-based prescription drug, Epidiolex, for specific epilepsy indications. This approval is for a manufactured drug product for specific indications and is not directly relevant to the compounding pharmacy model.

Key distinction:  The compounding pharmacy model operates under pharmacy law, not FDA drug approval or supplement regulations. A 503A compounding pharmacy prepares medications pursuant to a prescription under state and federal pharmacy regulations. This is a separate regulatory pathway from both retail supplements and FDA-approved drugs.

6. The Compounding Pharmacy Pathway and Regulatory Compliance

Prescription Cannabinoid Care operates through the 503A compounding pharmacy model, which exists within a distinct regulatory framework from the retail supplement market or FDA drug approval pathways.

A licensed 503A compounding pharmacy prepares medications pursuant to valid prescriptions from licensed prescribers, under state and federal pharmacy regulations. This model predates the Farm Bill and is governed by a different regulatory framework than retail hemp-derived products.

The compounding pharmacy model operates within a separate regulatory framework from retail hemp-derived products. Compounding pharmacies are regulated by state boards of pharmacy and follow applicable federal pharmacy regulations, USP compounding standards, and applicable drug quality requirements. This framework is established and well-defined under existing pharmacy regulations.

For patients who are concerned about the regulatory future of retail cannabinoid products, the compounding pharmacy pathway represents a structured, clinically supervised alternative that operates within established healthcare and pharmacy regulatory frameworks.

This does not mean the compounding pathway is appropriate for every patient. Clinical evaluation determines individual eligibility. Not all evaluations result in a prescription. But the regulatory infrastructure supporting the pathway is stable in a way that the retail supplement market has not been.

7. What Patients Can Do Now

For patients who are currently using retail CBD and are uncertain about what regulatory changes mean for them, several steps are worth considering.

• Stay informed about regulatory developments. The FDA website and USDA hemp program page provide official information about regulatory changes as they are finalized.
• Review the products you are currently using. If the products contain THC at any level, regulatory changes may affect their availability or legal status depending on your state.
• Consider whether a clinical evaluation makes sense for your situation. If you have been using retail CBD to manage specific health concerns and want a structured, supervised alternative, a clinical evaluation is a concrete next step.
• Speak with your primary care clinician if you have questions about how your current CBD use interacts with your medications or health conditions. Not all clinicians have cannabinoid expertise, but the conversation is worth having.  If you are looking for a structured pathway that includes clinical evaluation, pharmacist preparation, and regulatory oversight, understanding how the prescription pathway works may help clarify your options.

The regulatory uncertainty affecting retail CBD is real. The clinical pathway that exists as an alternative is also real. For patients who want clinical guidance rather than regulatory uncertainty, the evaluation pathway described throughout this article is available now.

8. Frequently Asked Questions

Is retail CBD still legal?

Hemp-derived CBD products exist in a complex and actively evolving regulatory environment. The 2018 Farm Bill created the legal foundation for the retail CBD market, but FDA regulations and subsequent legislative changes have created ongoing uncertainty. The legal status of specific products depends on how they are formulated, marketed, and categorized, and this varies by state. For the most current information, consult official FDA and USDA sources.

Will I still be able to buy CBD at retail stores?

The retail availability of specific CBD products depends on how they are formulated and regulated under applicable state and federal law. Some products have already been affected by regulatory changes. Others may remain available. The specific products you currently use may or may not be affected depending on their formulation and product category.

Does the compounding pharmacy pathway change if CBD regulations change?

The 503A compounding pharmacy model operates under pharmacy law, which is a separate regulatory framework from supplement regulations or the Farm Bill. Compounding pharmacies are licensed and regulated by state pharmacy boards and follow federal pharmacy regulations. This framework exists independent of retail CBD market regulations and is not directly affected by Farm Bill changes.

Is Prescription Cannabinoid Care legal?

The compounding pharmacy model that Prescription Cannabinoid Care relies on is a federally recognized and established framework operating under state and federal pharmacy law. Prescriptions are filled by a licensed 503A compounding pharmacy pursuant to valid clinician prescriptions. Availability is subject to state pharmacy licensure. Cope Now currently operates in Colorado.

What if I want to keep using my current retail CBD product?

That is a decision you can make with your own clinician's guidance. The regulatory changes affecting retail CBD affect different products differently. If you want to understand whether your current product may be affected, reviewing FDA and USDA guidance for your specific product type is the appropriate starting point.

What is the difference between the retail CBD pathway and the compounding pharmacy pathway from a regulatory standpoint?

Retail CBD products sold as dietary supplements operate under FDA supplement regulations, which have not provided a clear approved pathway for CBD. The compounding pharmacy pathway operates under pharmacy law, which provides a well-established regulatory framework for patient-specific medication preparation pursuant to a prescription. These are distinct regulatory pathways with different standards, oversight structures, and compliance frameworks.

Should I stop using retail CBD because of regulatory changes?

That is a decision best made with clinical guidance based on your specific situation, medications, and health concerns. This article does not provide medical or legal advice. If you have concerns about your current CBD use and would like clinical guidance, a clinical evaluation is one option for obtaining a structured medical perspective.

What conditions does Cope Now evaluate?

Cope Now currently conducts clinician-guided evaluations for patients with concerns related to anxiety, sleep disruption, chronic pain, and recovery. Not all patients who seek evaluation will receive a prescription. The clinician determines what is appropriate based on individual assessment.

This article is for educational and informational purposes only. It is not medical or legal advice. Regulatory information reflects the landscape as of March 2026 and is subject to change. Cope Now provides access to licensed clinicians for clinical evaluation. Not all patients are eligible. No guarantee of prescription or outcome. Compounded formulations are not FDA-approved. Telehealth services currently available in Colorado only.

Check Your Eligibility

See if a clinical evaluation may be appropriate for you.